# A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

> **NCT00140621** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 6 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Agalsidase beta

## Key facts

- **NCT ID:** NCT00140621
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140621, "A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00140621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*